文献速递免疫规划妇幼与学校卫生

母亲孕期接种Tdap对婴儿抗体应答的影响:一项开放标签随机对照试验

Infant antibody levels following 10-valent pneumococcal-protein D conjugate and DTaP-Hib vaccinations in the first year of life after maternal Tdap vaccination: An open-label, parallel, randomised controlled trial.
PubMed 文献 · Vaccine · 2020-05-21

该开放标签随机平行对照试验将孕妇分为孕30-32周接种Tdap组(n=58)和产后48小时内接种组(n=60),婴儿在3、5、11月龄接种DTaP-IPV-Hib-HepB和PHiD-CV10。结果显示,孕期接种组婴儿基础免疫后白喉类毒素(DT)抗体和肺炎链球菌19F型抗体显著低于对照组,但破伤风类毒素(TT)、Hib PRP及其他9种肺炎球菌血清型抗体无差异;加强免疫后除DT外无显著差异。

要点

  • 孕期接种Tdap可显著降低婴儿基础免疫后DT抗体水平(GMC比值0.4,95%CI 0.3-0.6)。
  • 孕期接种Tdap组婴儿肺炎链球菌19F型抗体显著低于对照组,其他血清型无差异。
  • 加强免疫后除DT外,各组抗体水平无显著差异。

核心结论

  • 母亲孕期接种Tdap不仅显著干扰婴儿对DT的抗体应答,也干扰对以DT突变体CRM197为载体蛋白的肺炎球菌结合疫苗的应答。

研究设计与样本

  • 开放标签、平行、随机对照试验,2014-2016年通过助产士招募孕妇,孕期接种组n=58,产后接种组n=60。
  • 婴儿在3、5、11月龄接种DTaP-IPV-Hib-HepB和PHiD-CV10,检测基础免疫和加强免疫前后DT、TT、Hib PRP及PHiD-CV10特异性IgG水平。

主要发现

  • 基础免疫后,孕期接种组DT抗体GMC比值为0.4(95%CI 0.3-0.6),显著低于对照组;TT抗体GMC比值为0.9(95%CI 0.6-1.2),无显著差异。
  • 孕期接种组肺炎链球菌19F型抗体显著低于对照组,Hib PRP及其他9种肺炎球菌血清型抗体无差异。
  • 加强免疫后,除DT外,各组抗体水平无显著差异。

临床怎么用

  • 设计国家婴儿免疫规划及选择疫苗时,需考虑母亲孕期接种Tdap对婴儿DT及含DT突变体载体蛋白结合疫苗应答的干扰。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Maternal antibody levels after Tdap vaccination during pregnancy may affect infant primary antibody responses to pertussis, Tetanus toxoid (TT), Diphtheria toxoid (DT) vaccinations and pneumococcal vaccines with diphtheria toxin mutants like CRM197 as carrier protein. METHODS: Mothers were recruited in an open label randomised parallel controlled trial in 2014-2016 through midwifes. They received Tdap [Boostrix] at 30-32 weeks of pregnancy (n = 58) or within 48 h after delivery (n = 60). Infants received DTaP-IPV-Hib-HepB [Infanrix Hexa] and 10-valent protein D conjugated pneumococcal conjugate vaccine (PHiD-CV10 [Synflorix]) at age 3, 5 and 11 months. We now report on infant specific IgG levels towards DT, TT, Haemophilus influenzae type b polyribosylribitol phosphate (Hib PRP) and PHiD-CV10 before and after primary- and booster vaccination as secondary study endpoints; pertussis antibodies were the primary endpoint of the study. This trial is registered in clinicaltrialsregister.eu (EudraCT 2012-004006-9) and trialregister.nl (NTR number NTR4314). FINDINGS: Post primary vaccinations, antibody levels to DT, but not TT, were significantly lower after Tdap vaccination during pregnancy compared to controls (GMC ratio 0.4, 95% CI 0.3-0.6 and 0.9, 95% CI 0.6-1.2, respectively). Antibodies to serotype 19F were significantly lower in the maternal Tdap group, whereas there were no differences in antibody levels to Hib PRP and the other 9 pneumococcal serotypes. Post booster vaccinations, no significant differences were observed, except for DT. INTERPRETATION: Maternal Tdap vaccination results in significant interference with infants responses not only to DT but also to conjugated pneumococcal vaccines containing DT mutants as carrier proteins. These interactions after maternal Tdap vaccination need to be taken into account when designing infants' national immunization schedules and choice of vaccines. FUNDING: The Dutch Ministry of Health, Welfare and Sport.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Barug D, Berbers GAM, van Houten MA, et al. Infant antibody levels following 10-valent pneumococcal-protein D conjugate and DTaP-Hib vaccinations in the first year of life after maternal Tdap vaccination: An open-label, parallel, randomised controlled trial. Vaccine. 2020. PMID: 32448624. doi:10.1016/j.vaccine.2020.04.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。